Table 4.
Antibiotic resistance rates of MRSA as reported from various studies in India
| Serial number | Antibiotic | Kaur et al.25 (n = 36) | INSAR study26 (n = 26,310) | Kali et al.39 (n = 102) | Saikia et al.40 (n = 96) | Abbas et al.26 (n = 143) | Arora et al.23 (n = 250) | Bhutia et al. (n = 15) |
|---|---|---|---|---|---|---|---|---|
| 1 | Gentamicine | 100 | 58.3 | 66.1 | 91.5 | 46.15 | 72.2 | 20 |
| 2 | Rifampin/rifampicin | 27.78 | – | – | – | – | – | 0 |
| 3 | Ceftaroline | 0 | – | – | – | – | – | – |
| 4 | Oxacillin (cefoxitin) | 100 | – | – | 100 | – | – | – |
| 5 | Ciprofloxacin | 100 | 79.3 | 80.6 | 91.5 | 54.54 | 67.8 | – |
| 6 | Moxifloxacin | 100 | – | – | – | – | – | – |
| 7 | Trimethoprim/sulfamethoxazole | 25 | 55.6 | 85.4 | 96.88 | 32.16 | – | 100 |
| 9 | Vancomycin | 0 | – | – | – | – | – | – |
| 10 | Teicoplanin | 0 | – | – | – | 16.08 | – | – |
| 11 | Telavancin | 0 | – | – | – | – | – | – |
| 12 | Tigecycline | 0 | – | – | – | – | – | – |
| 13 | Clindamycin | 97.22 | 46.6 | – | 56.25 | 46.15 | – | – |
| 14 | Daptomycin | 5.56 | – | – | – | – | ||
| 15 | Erythromycin | 100 | 70.8 | – | 81.25 | 62.93 | 61.7 | 33.33 |
| 16 | Linezolid | 2.78 | – | – | – | – | – | – |
| 17 | Quinupristin/dalfopristin | 5.56 | – | – | – | – | – | – |
MRSA, methicillin-resistant Staphylococcus aureus